Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Conduct a multicenter, open label Phase IIA trial of oral DCA in 40 surgical patients with
recurrent GBM who have clinically indicated debulking surgery planned. No patients will be
recruited at UF. Patients will be genotyped to establish safe dosing regimens and will be
randomized to receive DCA (N=20) or no DCA (N=20) for one week prior to surgery. Deidentified
blood and tumor tissue obtained at surgery will be assessed at UF for biochemical markers of
DCA dynamics.